William Blair Reaffirms “Outperform” Rating for Simulations Plus (NASDAQ:SLP)

Simulations Plus (NASDAQ:SLP)‘s stock had its “outperform” rating reiterated by stock analysts at William Blair in a report released on Thursday, Benzinga reports.

A number of other research analysts have also weighed in on the stock. Craig Hallum reissued a “buy” rating and set a $56.00 price target on shares of Simulations Plus in a research report on Wednesday, July 3rd. JMP Securities initiated coverage on Simulations Plus in a research note on Tuesday, July 16th. They issued a “market perform” rating on the stock. KeyCorp assumed coverage on Simulations Plus in a report on Monday, July 29th. They issued an “overweight” rating and a $47.00 target price for the company. Finally, BTIG Research dropped their price target on Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Thursday. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Simulations Plus currently has an average rating of “Moderate Buy” and an average target price of $54.50.

Simulations Plus Price Performance

Shares of SLP stock traded down $3.15 during trading hours on Thursday, reaching $30.83. The company had a trading volume of 471,607 shares, compared to its average volume of 128,168. The company has a market cap of $616.91 million, a price-to-earnings ratio of 64.17 and a beta of 0.69. The business has a fifty day simple moving average of $33.31 and a 200-day simple moving average of $40.83. Simulations Plus has a 12 month low of $29.37 and a 12 month high of $51.22.

Insider Transactions at Simulations Plus

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $35.18, for a total value of $703,600.00. Following the completion of the sale, the director now directly owns 3,501,592 shares of the company’s stock, valued at $123,186,006.56. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders sold a total of 60,750 shares of company stock worth $2,145,055 in the last quarter. Insiders own 20.90% of the company’s stock.

Institutional Trading of Simulations Plus

Several hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its holdings in Simulations Plus by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 1,135,105 shares of the technology company’s stock valued at $46,710,000 after acquiring an additional 12,636 shares during the period. Dimensional Fund Advisors LP grew its stake in Simulations Plus by 10.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 414,005 shares of the technology company’s stock worth $20,128,000 after buying an additional 37,992 shares in the last quarter. Wasatch Advisors LP lifted its stake in Simulations Plus by 36.5% during the first quarter. Wasatch Advisors LP now owns 381,693 shares of the technology company’s stock worth $15,707,000 after purchasing an additional 102,135 shares during the last quarter. Kennedy Capital Management LLC boosted its holdings in shares of Simulations Plus by 3.2% in the 1st quarter. Kennedy Capital Management LLC now owns 229,439 shares of the technology company’s stock worth $9,441,000 after purchasing an additional 7,077 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Simulations Plus by 5.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 222,317 shares of the technology company’s stock valued at $10,809,000 after purchasing an additional 11,048 shares during the last quarter. Institutional investors own 78.08% of the company’s stock.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.